Data gathered: November 27
Alternative Data for Soleno Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 53 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| Google Trends | 13 | Sign up | Sign up | Sign up |
| Patents | 9 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,534 | Sign up | Sign up | Sign up |
| Twitter Mentions | 25 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 73 | Sign up | Sign up | Sign up |
About Soleno Therapeutics
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
| Price | $55.84 |
| Target Price | Sign up |
| Volume | 364,700 |
| Market Cap | $2.47B |
| Year Range | $37.14 - $59.18 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceNovember 27 - GlobeNewswire |
|
 |
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi SyndromeNovember 25 - Yahoo |
Soleno Therapeutics : Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended Release Tablets in Prader Willi Syndrome Form 8 KNovember 25 - Finnhub |
|
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024November 14 - Finnhub |
|
 |
Soleno Therapeutics (NASDAQ:SLNO) Receives “Buy” Rating from HC WainwrightNovember 13 - ETF Daily News |
 |
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn SituationNovember 11 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 49M | -49M | -77M | -80M | -1.830 |
| Q2 '24 | 0 | 11M | -11M | -22M | -24M | -0.570 |
| Q1 '24 | 0 | 9M | -9M | -21M | -23M | -0.590 |
| Q4 '23 | 3.4M | 4.6M | -4.6M | -11M | -13M | -0.330 |
| Q3 '23 | 0 | 3.3M | -3.3M | -11M | -9.9M | -0.950 |
Insider Transactions View All
| Hirano Patricia C filed to sell 108,932 shares at $50.2. October 3 '24 |
| Mackaness James H filed to sell 119,172 shares at $50.2. October 3 '24 |
| Yen Kristen filed to sell 81,465 shares at $50.2. October 3 '24 |
| Anish Bhatnagar filed to sell 719,553 shares at $50.2. October 3 '24 |
| Hirano Patricia C filed to sell 109,251 shares at $49.3. October 3 '24 |
Similar companies
Read more about Soleno Therapeutics (SLNO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Soleno Therapeutics?
The Market Cap of Soleno Therapeutics is $2.47B.
What is the current stock price of Soleno Therapeutics?
Currently, the price of one share of Soleno Therapeutics stock is $55.84.
How can I analyze the SLNO stock price chart for investment decisions?
The SLNO stock price chart above provides a comprehensive visual representation of Soleno Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Soleno Therapeutics shares. Our platform offers an up-to-date SLNO stock price chart, along with technical data analysis and alternative data insights.
Does SLNO offer dividends to its shareholders?
As of our latest update, Soleno Therapeutics (SLNO) does not offer dividends to its shareholders. Investors interested in Soleno Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Soleno Therapeutics?
Some of the similar stocks of Soleno Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.